Business Wire

Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssist

1.7.2020 14:00:00 EEST | Business Wire | Press release

Share

The first published United States experience of patients who received Abiomed’s newest heart pump, Impella 5.5 with SmartAssist, finds 84% of the patients survived to explant with 76% native heart recovery. The study was published in the July edition of the American Society for Artificial Internal Organs (ASAIO) Journal.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005293/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Impella 5.5 with SmartAssist is featured on the front cover of the July 2020 edition of the ASAIO Journal. (Photo: Business Wire)

The study examined the outcomes of the first 55 patients treated with Impella 5.5 with SmartAssist at Cleveland Clinic, Hackensack University Medical Center/Hackensack Meridian Health and Cedars-Sinai Medical Center. Study authors and cardiac surgeons Ed Soltesz, MD, Mark Anderson, MD, and Danny Ramzy, MD, conclude Impella 5.5 with SmartAssist is safe and effective for a number of challenging clinical scenarios, including AMI cardiogenic shock.

“This report demonstrates the benefit of unloading cardiogenic shock patients and it is encouraging to see real-world data demonstrate improved survival rates with use of Impella 5.5 with SmartAssist,” said Danny Ramzy, MD, assistant professor, surgical director of the lung transplant program, and director, robotic and minimally invasive cardiac surgery at Cedars-Sinai Medical Center. “The continued use of best practices, techniques and innovative technology like Impella allows us to provide better patient care that improves outcomes and quality of life.”

In September 2019, Impella 5.5 with SmartAssist received FDA pre-market approval (PMA) for safety and efficacy in the therapy of cardiogenic shock for up to 14 days. It is a micro-axial, surgically implanted, temporary heart pump that unloads the left ventricle, reduces ventricular work, and provides the circulatory support necessary to allow native heart recovery and early assessment of residual myocardial function. Its benefits include:

  • Ease of insertion through the axillary artery or the anterior aorta
  • Designed for long-duration support with durable ceramic bearings, no pigtail to minimize adhesions, and ability for patient ambulation
  • Forward flow with maximum unloading, to provide end organ and coronary perfusion, while allowing the heart to rest
  • Better patient management with intelligent device positioning, management, and weaning with SmartAssist technology
  • Equipped with Impella Connect , a cloud-based monitoring and collaborative patient management platform that allows for remote monitoring of the Impella console. During the COVID-19 crisis, this online, HIPAA-compliant monitoring service is being provided at no cost to help medical providers manage patients 24/7.

The 55 patients in the study were implanted with Impella 5.5 with SmartAssist between October 16, 2019 and March 4, 2020. Specifically, the study authors determined:

  • 35 patients (63.6%) were successfully weaned off the technology.
  • 11 patients (20.0%) went on to receive another therapy, two patients (3.6%) expired while on support, and seven patients (12.7%) had care withdrawn.
  • 76.1% of survivors recovered native heart function.
  • There were no device-related strokes, hemolysis, or limb ischemia observed.
  • The results demonstrate Impella provides dependable acute mechanical circulatory support for patients who need it by stabilizing their hemodynamics during treatment.

ABOUT IMPELLA HEART PUMPS

The Impella 2.5® and Impella CP® devices are U.S. FDA PMA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. The Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella RP® is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery. The Impella RP is also authorized for emergency use by healthcare providers (HCPs) in the hospital setting for providing temporary right ventricular support for up to 14 days in critical care patients with a body surface area ≥1.5 m2, for the treatment of acute right heart failure or decompensation caused by complications related to coronavirus disease 2019 (COVID‐19), including pulmonary embolism (PE). The Impella RP has not been cleared or approved for the treatment of acute right heart failure or decompensation caused by complications related to COVID-19. The Impella RP has been authorized for the above emergency use by FDA under an EUA and has been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

In Europe, the Impella 2.5, Impella CP and Impella CP with SmartAssist are CE marked for treatment of high-risk PCI and AMI cardiogenic shock patients for up to 5 days. Impella 5.0 and Impella LD are CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 10 days. The Impella 5.5 with SmartAssist is CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 30 days. The Impella RP is CE marked to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, open-heart surgery, or refractory ventricular arrhythmia.

To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit www.impella.com.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella BTR, Impella ECP, CVAD Study and STEMI DTU Study are pending trademarks of Abiomed, Inc.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with the scope, scale and duration of the impact of the COVID-19 pandemic, development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sarah Karr
Communications Manager
978-882-8211
skarr@abiomed.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Would You Let AI Manage Your Next Trip?17.11.2026 14:06:00 EET | Press release

AI is already transforming the traveler journey, helping people discover, plan and navigate their trips. The question is how far travelers will let AI make decisions for them in the future: booking, paying, changing plans and recovering from disruption. The next decade could be shaped not by how convincingly AI recommends a trip, but by whether travelers have the confidence in it to see the journey through from start to finish. That challenge sits at the heart of The Intelligent Journey 2032, a global scenario study by Stratforma and Professor Steven Weber of the Graduate School, UC Berkeley School of Information, commissioned by Amadeus. Four ways journeys could change by 2032 The study explores four possible futures for travel in 2032.1 Traveler Served? AI works behind the scenes to make journeys smoother, but people remain cautious about letting it take control. Machine vs. Machine. A traveler's AI agent interacts directly with the AI systems of airlines, hotels and other providers,

Iconic Raises $10M to Build Software That Understands the World’s Biggest Projects17.11.2026 14:01:00 EET | Press release

Iconic has raised $10 million in seed funding led by Peak Capital, with participation from Bridford Group, Common Magic, Graduate Ventures, NP-Hard, and Tiny VC. Since its founding in mid-2025, Iconic has signed five clients in energy, infrastructure, and AI infrastructure: a global energy major, a leading European utility, a major European airport, a European rail infrastructure owner, and a global contractor building semiconductor fabs and data centers. Each spends over $1 billion annually on capital projects. An estimated $15 trillion is invested in capital projects annually, yet fewer than 3% are delivered on time, on budget, and to plan. Capital projects rarely fail because of engineering complexity, but because decisions are made without a complete understanding of the project. Information is fragmented across documents and systems shared by owners, contractors, and engineering firms. Decisions are hard to reverse, with consequences lasting years through delays, claims, and cost

Quaise Energy Signs 50 MW Geothermal Power Purchase Agreement with Google17.11.2026 13:50:00 EET | Press release

Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that Google has signed a power purchase agreement (PPA) for 50 megawatts (MW) of superhot geothermal power from Project Obsidian, Quaise’s flagship project in Central Oregon. Once online, this always-on, carbon-free energy is slated to support Google’s existing data center operations in The Dalles, Ore. and the region’s communities. The agreement will help catalyze the commercial development of superhot geothermal energy, providing benefits for ratepayers and helping protect the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117923219/en/ Beginning as early as 2030, Google will purchase 50 MW of power from Project Obsidian. The initial phase of development will use conventional drilling technology to access superhot geothermal conditions at commercial scale. Superhot geothermal is a virtually limitless energy sourc

Nowhere to Sit, Nothing to Do: Europe’s Biggest Airports Fall Short for Passengers17.11.2026 13:24:00 EET | Press release

One in four of Europe’s 50 biggest airports scores below the global average on all four parts of the experience passengers rated, according to AirHelp data covering 279 airports worldwide. Passengers rated each airport on wait times, restaurants, seating and entertainment. Twelve airports, including Dublin, Manchester, Lisbon, London Luton and Milan Bergamo, came in below the global average on all four. Only four beat all four averages: Zurich, Warsaw, Naples and Ankara. Entertainment is the weak spot almost everywhere Entertainment was the lowest-rated part of the experience at 45 of the 50 airports, averaging 6.5 out of 10, with more than half of the airports falling below the global average of 6.7. Seven airports scored less than 6, including Manchester, Stansted, Dublin and Oslo. The data also suggests that passengers who can’t find a seat usually have nothing to do either: 22 of the 50 airports score below the global average for both seating and entertainment. Many airports offer

Infobip Expands Relationship With Anthropic With Verified Claude Connector for Global Messaging17.11.2026 11:00:00 EET | Press release

Global AI-first cloud communications platform Infobip has expanded its collaboration with Anthropic with the launch of the Infobip Message connector in the Claude Marketplace. The Anthropic-verified connector enables developers, enterprises and builders using Claude to add global messaging capabilities to AI agents without building separate integrations for individual communication channels. The integration connects Claude with Infobip’s global communications infrastructure, enabling AI agents to send messages across SMS, RCS, MMS and Viber through a single connector. Using Infobip’s send and check status tools, agents can trigger outbound messages and track their delivery status, allowing them to incorporate real-world communication into automated workflows. For businesses building agentic AI applications, the connector can support use cases such as order confirmations, delivery updates and appointment reminders. Instead of developing and maintaining individual messaging integrations,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye